Market capitalization | $301.29m |
Enterprise Value | $362.59m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.64 |
P/S ratio (TTM) P/S ratio | 3.02 |
P/B ratio (TTM) P/B ratio | 7.48 |
Revenue growth (TTM) Revenue growth | 69.78% |
Revenue (TTM) Revenue | $99.68m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Alimera Sciences, Inc. forecast:
3 Analysts have issued a Alimera Sciences, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 100 100 |
70%
70%
|
|
Gross Profit | 74 74 |
60%
60%
|
|
EBITDA | 13 13 |
315%
315%
|
EBIT (Operating Income) EBIT | 0.85 0.85 |
108%
108%
|
Net Profit | -15 -15 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Head office | United States |
CEO | Richard Eiswirth |
Employees | 159 |
Founded | 2003 |
Website | www.alimerasciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.